Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 59Leukemia 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Gastrointestinal Stromal Tumors 12Leukemia, Myeloid, Chronic-Phase 11Neoplasms 5Blast Crisis 4Recurrence 3Bronchiolitis Obliterans Syndrome 3Synovitis, Pigmented Villonodular 2Philadelphia Chromosome 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myeloid 2Hematologic Diseases 2Bone Marrow Diseases 2Sarcoma 1Piebaldism 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplastic Processes 1Myeloproliferative Disorders 1Mucosal Lentiginous Melanoma 1Mastocytosis, Systemic 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1

Interventions

tofacitinib 6ibrutinib 6Imatinib Mesylate 5ofatumumab 4Rituximab 4nilotinib 3ruxolitinib 2bosutinib 2asciminib 2Pentostatin 2Oxycodone 2Naloxone 2KW-2478 2Dasatinib 2ziconotide 1sodium luminolate 1posaconazole 1pegfilgrastim 1oblimersen 1obinutuzumab 1montelukast 1mocetinostat 1lonafarnib 1ixekizumab 1fludarabine 1fenebrutinib 1canakinumab 1baricitinib 1abexinostat 1Voriconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Bronchiolitis Obliterans Syndrome × nilotinib × Clear all
NCT01844765 2021-04-22

DIALOG

Novartis

Phase 2 Completed
59 enrolled 33 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myeloproliferative Disorders, Neoplastic Processes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00802841 2015-11-16

LASOR

Novartis

Phase 3 Completed
191 enrolled 13 charts
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01819389 2014-01-07

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

Hospital Universitario Dr. Jose E. Gonzalez

Phase 3 Completed
10 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡